DOI: 10.12890/2024_004279

Before quadriparesis with dysphagia can be attributed to COVID-19, all differential causes must be excluded

Authors

  • Josef Finsterer Neurology Department, Neurology & Neurophysiology Centre, Vienna, Austria
  • Sounira Mehri Biochemistry Laboratory, LR12ES05 “Nutrition-Functional Foods and Vascular Health”, Faculty of Medicine, Monastir, Tunisia

fipaps@YAHOO.DE

Keywords

SARS-CoV-2 infection, dysphagia, botulinum toxin, quadruparesis, critically ill myopathy

View the entire article

Downloads

References

  1. Canta R, Vestito L, Castellini P, Trompetto C, Mori L, De Giovanni A, et al. Successful treatment of post COVID-19 neurogenic dysphagia with botulinum toxin. Eur J Case Rep Intern Med 2023;10:004105.
  2. Schefold JC, Wollersheim T, Grunow JJ, Luedi MM, Z'Graggen WJ, Weber-Carstens S. Muscular weakness and muscle wasting in the critically ill. J Cachexia Sarcopenia Muscle 2020;11:1399–1412.
  3. Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg 2021;57:55.
  4. Sonneville R, Dangayach NS, Newcombe V. Neurological complications of critically ill COVID-19 patients. Curr Opin Crit Care 2023;29:61–67.

Published

2024-01-17

Issue

Vol. 11 No. 2 (2024)

Categories

How to Cite

1.
Finsterer J, Mehri S. Before quadriparesis with dysphagia can be attributed to COVID-19, all differential causes must be excluded. EJCRIM [Internet]. 2024 Jan. 17 [cited 2026 Nov. 3];11(2). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4279

Most read articles by the same author(s)